2PD Dr. med. C. Alexiou,R. Jurgons,R. Schmid,W. Erhardt,F. Parak,C. Bergemann,H. Iro. Magnetisches Drug Targeting—ein neuer Ansatz in der lokoregion?ren Tumortherapie mit Chemotherapeutika[J] 2005,HNO(7):618～622
二级参考文献14
1Wadler S. New developments in treatment of ovarian cancer [J].Expert Opin Investig Drugs, 2001, 10(6): 1167 - 1172.
2Harries M, Kaye SB. Recent advances in the treatment of epithelial ovarian cancer [J]. Expert Opin lnvestig Drugs, 2001,10(9): 1715 - 1724.
3Ozols Robert F. Future directions in the treatment of ovarian cancer [ J ]. Semin Oncol, 2002, 29 ( 1 suppl ) : 32 - 42.
4Kronenwett R. Hass R. Antisense strategies for the treatment of hematological malignancies and solid tumors [J] . Ann Hematol,1998,77(1 -2): 1 - 12.
5Guha C, Guha U. Tribius S, et al. Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors [J]. Gene Ther, 2000, 7( 10): 852 - 858.
6Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived Growth Factor Receptor reduces interstitial hypertension and increase transcapillary transport in tumor [J].Cancer Res, 2001, 61 (7): 2929 - 2934.
7King BI, Carter D, Foellmer HG, et al. Neu proto-oncogene amplification and expression in overian adenocarcinoma cell lines[J]. Am J pathol, 1992,140(1):23-31.
8Funato T, Kozawa K, Fujimaki S, et al. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the HER-2/neu(C-erbB-2) Gene [J]. Chemotherapy, 2001, 47(4): 297-303.
9O'Dwyer PJ, Stevenson JP, Gallagher M, et al. C-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide Isis 5132(CGP 68936A) [J] . Clin Cancer Res, 1999, 5(12): 3977 - 3982.
10Eppenberger Castori S, Kueng W, Benz C, et al. Prognosis and predictive significance of erbB-2 breast tumor levels measured by enzyme immunoassay [J]. J Clin oncol, 2001, 19(3):645 -656.
5Andre T, Boni C, Mounedji - Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med,2004,350(23) :2 343.
6Wolmark N,Rockette H, Mamounas E,et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin,fluorouracil and levamisole, and fluorouracil, leucovorin,and levamisole in patients Dukes B and C carcinoma of the colon:result from National Surgical Adjuvant Breast and Bowel Project[J]. J Glin Oncol, 1999,17 (11 ) :3 553 - 3 559.
7Andre T,Colin P,Louvet C,et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage Ⅱ and Ⅲ colon cancer:Results of a randomized trial [J]. J Clin Oncol,2003,21 ( 15 ) :2 896.
9Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study) : Efficacy results of a phase Ⅲ trial [J]. Proc Am Soc Clin Oncol, 2004,22:3 509.
10Cutsem EV, Hof PM, Harper P, et al. Oral capeeitabine vs intravenous 5-fluorouracil and leucovorin:integrated efficacy data and novel analyses from two large, randomized, phase Ⅲ trials[J]. Br J Cancer, 2004, 90(6) : 1 190 - 1 197.
